From: Machine learning models in evaluating the malignancy risk of ovarian tumors: a comparative study
Histologic Type | N | % | |
---|---|---|---|
Benign | 1196 | 76.91 | |
Endometrioid Cystadenoma | 420 | 27.01 | |
Teratoma | 221 | 14.21 | |
Serous Cystadenoma | 192 | 12.35 | |
Mucinous Cystadenoma | 78 | 5.02 | |
Fibroma and Related Tumors | 71 | 4.57 | |
Simple Cyst | 67 | 4.31 | |
Mesosalpinx cyst | 54 | 3.47 | |
Salpingitis | 47 | 3.02 | |
Fibrothecoma | 19 | 1.22 | |
Paraovarian Cyst | 5 | 0.32 | |
Sertoli-Leydig Cell Tumor (High Grade) | 5 | 0.32 | |
Benign Brenner Tumor | 4 | 0.26 | |
Seromucinous Cystadenoma | 4 | 0.26 | |
Other ovarian benign lesion | 9 | 0.58 | |
Borderline ovarian tumor | 53 | 3.41 | |
Serous | 28 | 1.80 | |
Mucinous | 21 | 1.35 | |
Endometrioid | 2 | 0.13 | |
Brenner Tumor | 2 | 0.13 | |
Primary ovarian malignant | 252 | 16.21 | |
Serous Adenocarcinoma | 167 | 10.74 | |
Clear Cell Carcinoma | 30 | 1.93 | |
Endometrioid Adenocarcinoma | 25 | 1.61 | |
Mucinous Adenocarcinoma | 9 | 0.58 | |
Granulosa Cell Tumor | 9 | 0.58 | |
Carcinosarcoma | 1 | 0.06 | |
Sarcoma | 3 | 0.19 | |
Neuroendocrine Carcinoma | 1 | 0.06 | |
Sertoli-Leydig Cell Tumor (Low Grade) | 1 | 0.06 | |
Fibrosarcoma | 1 | 0.06 | |
Malignant Teratoma | 3 | 0.19 | |
Dysgerminoma | 1 | 0.06 | |
Yolk sac tumor | 1 | 0.06 | |
Ovarian metastasis | 54 | 3.47 |